EUVIMEDObjevte EUVIMED
Übersichtsarbeit

Novel insights into the GCN2 pathway and its targeting. Therapeutic value in cancer and lessons from lung fibrosis development

Marie Piecyk, Carole Ferraro-Peyret, David Laville, Frédéric Perros, Cedric Chaveroux iD

The FEBS Journal · 2024

DOI: 10.1111/febs.17203 ↗

At a glance

Übersichtsarbeit in The FEBS Journal, 2024. Written by Marie Piecyk and 4 co-authors. Institution: Department of Biochemistry and Molecular Biology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France. Major MEDLINE topics: Protein Serine-Threonine Kinases, Signal Transduction, Neoplasms. Cited 18 times so far (Crossref); 202 references. Funded by: Institut National Du Cancer, Ligue Contre le Cancer, Fondation ARC pour la Recherche sur le Cancer.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Defining the mechanisms that allow cells to adapt to environmental stress is critical for understanding the progression of chronic diseases and identifying relevant drug targets. Among these, activation of the pathway controlled by the eIF2‐alpha kinase GCN2 is critical for translational and metabolic reprogramming of the cell in response to various metabolic, proteotoxic, and ribosomal stressors. However, its role has frequently been investigated through the lens of a stress pathway signaling via the eIF2α‐activating transcription factor 4 (ATF4) downstream axis, while recent advances in the field have revealed that the GCN2 pathway is more complex than previously thought. Indeed, this kinase can be activated through a variety of mechanisms, phosphorylate substrates other than eIF2α, and regulate cell proliferation in a steady state. This review presents recent findings regarding the fundamental mechanisms underlying GCN2 signaling and function, as well as the development of drugs that modulate its activity. Furthermore, by comparing the literature on GCN2's antagonistic roles in two challenging pathologies, cancer and pulmonary diseases, the benefits, and drawbacks of GCN2 targeting, particularly inhibition, are discussed.

Subjects

MeSH terms (MEDLINE)

Protein Serine-Threonine KinasesSignal TransductionNeoplasmsHumansAnimalsPulmonary FibrosisActivating Transcription Factor 4Eukaryotic Initiation Factor-2Molecular Targeted Therapy

Author keywords

GCN2cancerlung diseasespharmacological modulation

Substances

EIF2AK4 protein, humanProtein Serine-Threonine KinasesActivating Transcription Factor 4Eukaryotic Initiation Factor-2

Authors and institutions

  • Department of Biochemistry and Molecular Biology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
  • Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Faculty of Medicine and Maieutic Lyon Sud, University Lyon I, Oullins, France.
  • Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, France.
  • Hospices Civils de Lyon, Plateforme AURAGEN, France.
  • Department of Pathology, Hospices Civils de Lyon, East Hospital Group, Bron, France.
  • Laboratoire CarMeN, UMR INSERM U1060/INRA U1397, University of Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France.

ORCID profiles: Cedric Chaveroux

Funding

  • Institut National Du Cancer
  • Ligue Contre le Cancer
  • Fondation ARC pour la Recherche sur le Cancer

Cite

APA

Piecyk, M., Ferraro-Peyret, C., Laville, D., Perros, F., & Chaveroux, C. (2024). Novel insights into the GCN2 pathway and its targeting. Therapeutic value in cancer and lessons from lung fibrosis development. The FEBS Journal. https://doi.org/10.1111/febs.17203

Vancouver

Piecyk M, Ferraro-Peyret C, Laville D, Perros F, Chaveroux C. Novel insights into the GCN2 pathway and its targeting. Therapeutic value in cancer and lessons from lung fibrosis development. The FEBS Journal. 2024. doi:10.1111/febs.17203

BibTeX
@article{Piecyk2024,
  author = {Piecyk, Marie and Ferraro-Peyret, Carole and Laville, David and Perros, Frédéric and Chaveroux, Cedric},
  title = {Novel insights into the GCN2 pathway and its targeting. Therapeutic value in cancer and lessons from lung fibrosis development},
  journal = {The FEBS Journal},
  year = {2024},
  doi = {10.1111/febs.17203}
}
Start for free →